Entrada Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Entrada Therapeutics has been growing earnings at an average annual rate of 19%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 130.6% per year. Entrada Therapeutics's return on equity is 24.3%, and it has net margins of 43.6%.
Belangrijke informatie
19.0%
Groei van de winst
66.0%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | 130.6% |
| Rendement op eigen vermogen | 24.3% |
| Nettomarge | 43.6% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding
Oct 17
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher
Aug 23Entrada Therapeutics: A Complicated Tale
Jun 16Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry
May 29These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
Mar 19This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Nov 09Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
May 26Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 14Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
Mar 08We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Sep 11Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Aug 11We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
May 28We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Jan 31Opbrengsten en kosten
Hoe Entrada Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 239 | 104 | 35 | 0 |
| 31 Mar 24 | 163 | 23 | 34 | 0 |
| 31 Dec 23 | 129 | -7 | 32 | 0 |
| 30 Sep 23 | 87 | -22 | 34 | 67 |
| 30 Jun 23 | 43 | -82 | 33 | 0 |
| 31 Mar 23 | 25 | -80 | 32 | 0 |
| 31 Dec 22 | 0 | -95 | 31 | 0 |
| 30 Sep 22 | 0 | -88 | 27 | 12 |
| 30 Jun 22 | 0 | -78 | 24 | 23 |
| 31 Mar 22 | 0 | -64 | 19 | 30 |
| 31 Dec 21 | 0 | -51 | 15 | 36 |
| 30 Sep 21 | 0 | -41 | 11 | 30 |
| 30 Jun 21 | 0 | -34 | 9 | 25 |
| 31 Mar 21 | 0 | -29 | 7 | 23 |
| 31 Dec 20 | 0 | -27 | 6 | 21 |
Kwaliteitswinsten: TRDA has high quality earnings.
Groeiende winstmarge: TRDA became profitable in the past.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: TRDA has become profitable over the past 5 years, growing earnings by 19% per year.
Versnelling van de groei: TRDA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Winst versus industrie: TRDA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: TRDA's Return on Equity (24.3%) is considered high.